slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
221,341-221,370 of 319,975
63
The slide illustrates the mechanism of action for two therapeutic modalities derived from the same TCR discovery platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
64
The slide uses a comparative framework to explain the safety profile of their technology platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
65
The slide uses a flywheel-style circular diagram to represent the iterative nature of the data platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
66
The slide highlights the breadth of the company's intellectual property protection across major global regions.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
67
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
68
The slide uses a grid layout with headshots and professional titles for 9 executives.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Team1 hit
69
The slide highlights the trans-atlantic nature of the organization with specific operational focus areas per site.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Team1 hit
70
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
71
Includes waterfall plot and spider plot for RECIST 1.1 response metrics.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
72
Includes waterfall plot and spider plot (change in tumor size over time).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
73
Data cut-off Sep 30, 2023. N=21 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
74
Data cut-off Sep 30, 2023. N=28 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
75
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
01
Includes date and ticker symbol.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
04
The slide uses a structured grid layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
05
The slide uses a cause-and-effect structure to map platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
06
Uses a human anatomy diagram to map therapeutic areas to diseases; includes a pyramid at the bottom highlighting 'Other diseases' and the key differentiator 'Overcoming neurotoxicity'.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
07
Includes a cartoon illustration of a cell/virus character.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a structural diagram to highlight the specific modifications (COBRA Binder) that differentiate NXC-201 from the reference therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
12
The slide compares HSL (Heavy-chain-led) vs LSH (Light-chain-led) configurations, demonstrating superior performance for HSL.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
13
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
15
The slide uses a biological structural diagram to illustrate the proprietary nature of the COBRA binding domain compared to standard CAR-T constructs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
16
Includes comparative data points for transduction efficiency and experimental data for signaling and exhaustion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
17
The slide uses a multi-panel line chart to compare clinical outcomes across three different therapies.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit